The Kratom Conundrum: Did Lobbying Influence Trump’s Opioid Policy U-Turn?
The Trump administration backed off a full ban on MGPI, a potent opioid compound found in some kratom products, and proposed allowing levels that HHS and the DEA have not found safe. A published New York Times investigation found the reversal followed industry lobbying and millions in Republican donations from a kratom executive whose company […]